Arabic Arabic English English French French German German
dark

KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. today provided an update on the clinical trial progress for KVD900 in development for oral on-demand treatment of hereditary angioedema (HAE). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

S’pore’s health science innovations get AI boost in SingHealth, SGInnovate tie-up

Next Post

IPA Announces Resignation of Director

Related Posts
Total
0
Share